Publications by authors named "Gaetano Finocchiaro"

Are you Gaetano Finocchiaro?   Register this Author

Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O-Methylguanine-DNA Methyltransferase Biomarker Analyses.
J Clin Oncol 2017 Jan 5;35(3):343-351. Epub 2016 Dec 5.
Timothy Cloughesy, University of California, Los Angeles; Lawrence Recht, Stanford Cancer Center, Stanford; Carlos Bais, Thomas Sandmann, Jean-Marie Bruey, Hartmut Koeppen, Bo Liu, Wendy Verret, See-Chun Phan, and David S. Shames, Genentech, South San Francisco, CA; Tom Mikkelsen, Henry Ford Hospital, Detroit, MI; Gaetano Finocchiaro, Istituto Neurologico Carlo Besta, Milan; Alba A. Brandes, Azienda Unità Sanitaria Locale-Istituto di Ricovero e Cura a Carattere Scientifico Institute of Neurologic Sciences, Bologna, Italy; Cristóbal Belda-Iniesta, Centro Integral Oncológico Clara Campal, University Hospital HM Sanchinarro, Madrid; Estela Pineda, Hospital Clinic of Barcelona; Carmen Balana, Institut Català d'Oncologia Badalona Hospital Germans Trias I Pujol, Barcelona, Spain; Olivier L. Chinot, Aix-Marseille Université Assistance Publique-Hôpitaux de Marseille, Marseille, France; David R. Macdonald, London Health Sciences Centre, London, Ontario, Canada; Manfred Westphal, University Clinic Hamburg-Eppendorf, Hamburg, Germany; Kirsten Hopkins, Bristol Haematology and Oncology Centre, Bristol, United Kingdom; and Michael Weller, University Hospital Zurich, Zurich, Switzerland.

Human glioblastoma stem-like cells accumulate protoporphyrin IX when subjected to exogenous 5-aminolaevulinic acid, rendering them sensitive to photodynamic treatment.
J Photochem Photobiol B 2016 Oct 27;163:203-10. Epub 2016 Aug 27.
Institute for Transplantation Diagnostics and Cell Therapeutics, Heinrich-Heine University Hospital Düsseldorf, Moorenstrasse 5, 40225 Düsseldorf, Germany. Electronic address:

Safe and Reproducible Preparation of Functional Dendritic Cells for Immunotherapy in Glioblastoma Patients.
Stem Cells Transl Med 2015 Oct 13;4(10):1164-72. Epub 2015 Aug 13.
Cell Therapy Production Unit, Laboratory of Cellular Neurobiology, Cerebrovascular Unit, and Unit of Molecular Neuro-Oncology, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.

Radiosurgery reirradiation for high-grade glioma recurrence: a retrospective analysis.
Neurol Sci 2015 Aug 25;36(8):1431-40. Epub 2015 Mar 25.
Radiotherapy Unit, Neurosurgery Department, Fondazione IRCCS Istituto Neurologico Carlo Besta, Via Celoria 11, 20133, Milan, MI, Italy,

Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas.
N Engl J Med 2015 Jun 10;372(26):2481-98. Epub 2015 Jun 10.

EGFR amplified and overexpressing glioblastomas and association with better response to adjuvant metronomic temozolomide.
J Natl Cancer Inst 2015 May 3;107(5). Epub 2015 Mar 3.
Pathology (MC, BL, MFB, DM, VP, FF, PLP) and Pharmacology Units (CB, MP), Department of Molecular and Translational Medicine, University of Brescia and National Institute of Neuroscience, Italy; Medical Oncology (SG), Neurosurgery (LB), Radiation Oncology (MB), and Neuroradiology Departments (RL), Spedali Civili of Brescia, University of Brescia, Italy; Neural Stem Cell Biology Unit, Division of Regenerative Medicine, Stem Cells & Gene Therapy, San Raffaele Scientific Institute, Milan (SM, RG); Pathology Unit, Department of Surgical and Morphological Sciences, University of Insubria, Italy (DF); Neurological Institute Besta, Milan, Italy (SP, GF); Herbert Irving Comprehensive Cancer Center, Department of Pathology & Cell Biology and Department of Medicine, Division of Digestive and Liver Diseases, Columbia University, New York, NY (PD); IRCCS San Camillo Hospital, Venice, Italy (MP).

Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes.
Neurology 2014 Sep 22;83(13):1200-6. Epub 2014 Aug 22.
From Sorbonne Universités (M.L., B.B., K.M., A.-L.D.S., A.R., M.R., P.C., O.S., M.S.), UPMC Univ Paris 06, Inserm, CNRS, UM 75, U 1127, UMR 7225, ICM, Paris; Institut du Cerveau et de la Moelle épinière (ICM) (B.B., Y.M.), Plateforme de Génotypage Séquençage, Paris; Groupe Hospitalier Pitié Salpêtrière, Laboratoire de Neuropathologie R Escourolle (K.M.), Onconeurothèque (K.M., Y.M., M.S.), and Groupe Hospitalier Pitié-Salpêtrière, Service de Neurologie 2 (A.-L.D.S., M.S.), AP-HP, Paris, France; National Neurological Institute C. Mondino (A.-L.D.S.), Pavia; Department of Neuroscience (M.R., P.C.), University of Padova; and Unit of Molecular Neuro-Oncology (R.P., G.F.), Fondazione IRCCS Carlo Besta, Milan, Italy.

Survival effect of first- and second-line treatments for patients with primary glioblastoma: a cohort study from a prospective registry, 1997-2010.
Neuro Oncol 2014 May 23;16(5):719-27. Epub 2014 Jan 23.
Unit of Neuroepidemiology, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy (F.N., I.T., A.F., M.F., G.F.); Unit of Neuroradiology, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy (M.G.B., L.F.); Department of Neurosurgery, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy; Department of Neurological Surgery, Johns Hopkins Medical School, Baltimore, Maryland (F.D.); Unit of Molecular Neuro-oncology, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy (G.F.); Unit of Neuropathology, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy (B.P.); Department of Neurology, Ospedale Alessandro Manzoni, Lecco, Italy (A.S.); Unit of Clinical Neuro-oncology, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy (A.S.).

Sox2 is required to maintain cancer stem cells in a mouse model of high-grade oligodendroglioma.
Cancer Res 2014 Mar 5;74(6):1833-44. Epub 2014 Mar 5.
Authors' Affiliations: Department of Biotechnology and Biosciences, University of Milano-Bicocca; Department of Molecular Neuro-Oncology, Fondazione I.R.C.C.S. Istituto Neurologico C.Besta; Department of Experimental Oncology, European Institute of Oncology at IFOM-IEO Campus; Tissue Processing Unit, The FIRC Institute of Molecular Oncology Foundation-IFOM, IFOM-IEO Campus, Milano; and IRCCS Azienda Ospedaliera Universitaria San Martino, IST Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy.

Operability of glioblastomas: "sins of action" versus "sins of non-action".
Neurol Sci 2013 Dec 12;34(12):2107-16. Epub 2013 Mar 12.
Department of Neurosurgery, Fondazione Istituto Neurologico Carlo Besta, Via Celoria 11, 20133, Milan, Italy,

The MET oncogene is a functional marker of a glioblastoma stem cell subtype.
Cancer Res 2012 Sep 26;72(17):4537-50. Epub 2012 Jun 26.
IRCC-Institute for Cancer Research, Center for Experimental Clinical Molecular Oncology, University of Turin Medical School, Candiolo, Italy.

A critical role for regulatory T cells in driving cytokine profiles of Th17 cells and their modulation of glioma microenvironment.
Cancer Immunol Immunother 2011 Dec 21;60(12):1739-50. Epub 2011 Jul 21.
Unit of Molecular Neuro-Oncology, Fondazione I.R.C.C.S. Istituto Neurologico C. Besta, via Celoria 11, 20133 Milan, Italy.

High-resolution genomic copy number profiling of glioblastoma multiforme by single nucleotide polymorphism DNA microarray.
Mol Cancer Res 2009 May 12;7(5):665-77. Epub 2009 May 12.
Division of Hematology and Oncology, Cedars-Sinai Medical Center, University of California at Los Angeles School of Medicine, Davis Building 5022 Room, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA.

The therapeutic potential of neural stem/progenitor cells in murine globoid cell leukodystrophy is conditioned by macrophage/microglia activation.
Neurobiol Dis 2006 Feb 30;21(2):314-23. Epub 2005 Sep 30.
Istituto Nazionale Neurologico C. Besta, Department of Experimental Neuro-Oncology and Diagnostics, via Celoria 11, 20133 Milano, Italy.

AVAREG: a phase II, randomized, noncomparative study of fotemustine or bevacizumab for patients with recurrent glioblastoma.
Neuro Oncol 2016 09 6;18(9):1304-12. Epub 2016 Mar 6.
Department of Medical Oncology, Bellaria-Maggiore Hospital, Azienda USL-IRCCS Institute of Neurological Sciences, Bologna, Italy (A.A.B., E.F.); Molecular Neuro-Oncology Unit, IRCCS Foundation Carlo Besta, Milan, Italy (G.F., M.E.); Department of Clinical and Experimental Oncology, Medical Oncology, Veneto Institute of Oncology- IRCCS Padua, Italy (V.Z., G.L.); Department of Medical Oncology, IRCCS San Raffaele, Milan, Italy (M.R.); Oncology Department, Santa Maria Hospital, Terni, Italy (C.C.); Department of Medical Oncology, Regina Elena National Cancer Institute, Rome, Italy (A.F.); E.O. Ospedale Galliera, Genova, Italy (M.C.); Oncology Unit, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy (E.M.); OPIS, Palazzo Aliprandi, Desio MB, Italy (M.M.); Roche S.p.A. Medical Affairs and CO, Monza, Italy (E.P.); Neuroradiology Department, Bellaria-Maggiore Hospital, Azienda USL-IRCCS Institute of Neurological Sciences, Ospedale Bellaria, Bologna, Italy (R.A.); Department of Biomedical and Neuromotor Science, University of Bologna, Section of Anatomic Pathology M. Malpighi-Bellaria Hospital, Bologna, Italy (V.E.).

A regulatory circuit of miR-125b/miR-20b and Wnt signalling controls glioblastoma phenotypes through FZD6-modulated pathways.
Nat Commun 2016 10 4;7:12885. Epub 2016 Oct 4.
Department of Neurology, Northwestern Brain Tumor Institute, The Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, USA.

Intertumoral Heterogeneity within Medulloblastoma Subgroups.
Cancer Cell 2017 06;31(6):737-754.e6
The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada; Developmental & Stem Cell Biology Program, The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON M5S 1A1, Canada; Division of Neurosurgery, The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada. Electronic address:

Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment.
Cancer Cell 2017 07;32(1):42-56.e6
Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA. Electronic address: